LGND News and Press, Ligand Pharmaceuticals Incorporated From 06/25/19

Intro to my approach You might have noticed in my previous articles how I mentioned this or that ticker as a result of running this or that screen. Indeed, I had, until 2 weeks ago, worked for over 6 months on performing hundreds and hundreds of backtests based on a number of multi-factor st...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target. PhoreMost has identified and validated the ta...

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...

The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts ...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this Read more ...

Short interest is often seen as a poor indicator for future price performance because it can represent conflicting signals. One one hand, its backward-looking as the stocks with the weakest operating and financial results typically decline against the market attracting further speculative sell...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Ve...

Shares of XOMA Corporation (XOMA) have lost over 90% of their value during the past 10 years and are in the red by roughly 30% in the past 12 months. In 2018, it was noted that, since formation (in 1981), the company burned through an astounding $1.2 billion of capital and failed to bring a dr...

Ligand Pharmaceuticals ( LGND +1.1% ) has acquired the economic rights to Novan's ( NOVN -0.5% ) SB206, a topical antiviral gel in Phase 3 development for skin infections, for $12M in upfront cash, up to $20M in milestones and tiered royalties of 7 - 10%. More news on: Ligand Pharmac...

Novan to immediately receive $12 million of non-dilutive capital Ligand to receive milestones and tiered royalty for North America SB206 molluscum indication Phase 3 molluscum trial to begin recruitment of patients this month Molluscum top line results targeted early during the ...